Phio Pharmaceuticals Corp. announced the departure of Dr. Gerrit Dispersyn from his role as President. Dr. Dispersyn joined the company in 2017 as Chief Development Officer and was subsequently appointed President and CEO in March 2019.

During his tenure as CEO Gerrit continued it's transition to become an immuno-oncology based enterprise originally initiated by Dr. Geert Cauwenbergh. Dr. Geert Cauwenbergh, former President and CEO, will take on the responsibility of Principle Executive Officer reporting to the Phio Board of Directors chaired by Robert Bitterman until such time as a satisfactory executive search has completed.